Profound Medical Corp. PROF
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 175.17% | 158.01% | 122.04% | 202.97% | 161.20% |
| Total Other Revenue | 20.12% | 20.94% | 18.08% | 33.79% | 31.15% |
| Total Revenue | 61.20% | 58.61% | 50.73% | 67.94% | 59.81% |
| Cost of Revenue | 48.80% | 41.79% | 29.15% | 14.03% | 17.77% |
| Gross Profit | 66.66% | 66.65% | 61.90% | 104.66% | 89.60% |
| SG&A Expenses | -7.63% | 14.63% | 38.54% | 42.00% | 55.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.55% | 18.07% | 31.11% | 34.44% | 40.64% |
| Operating Income | 16.41% | -4.84% | -24.78% | -25.93% | -36.08% |
| Income Before Tax | 20.08% | -20.99% | -52.13% | -24.84% | -45.92% |
| Income Tax Expenses | 415.91% | 23,700.00% | 12,700.00% | -271.43% | 128.95% |
| Earnings from Continuing Operations | 19.61% | -21.73% | -53.05% | -24.77% | -46.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.61% | -21.73% | -53.05% | -24.77% | -46.88% |
| EBIT | 16.41% | -4.84% | -24.78% | -25.93% | -36.08% |
| EBITDA | 16.08% | -5.94% | -26.67% | -27.46% | -37.91% |
| EPS Basic | 32.01% | -2.78% | -25.05% | 0.37% | -18.99% |
| Normalized Basic EPS | 32.43% | -2.18% | -24.37% | 0.33% | -18.16% |
| EPS Diluted | 32.01% | -2.78% | -25.05% | 0.37% | -18.99% |
| Normalized Diluted EPS | 32.43% | -2.18% | -24.37% | 0.33% | -18.16% |
| Average Basic Shares Outstanding | 20.90% | 21.37% | 22.10% | 22.54% | 20.82% |
| Average Diluted Shares Outstanding | 20.90% | 21.37% | 22.10% | 22.54% | 20.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |